Sudip Das

Dr. Das has over thirty years of teaching and research experience in the professional pharmacy and graduate programs in the USA and Canada.  He has supervised a number of postdoctoral, graduate and undergraduate research students, and was the key faculty responsible for the revitalization of the graduate program and research infrastructure in pharmaceutical sciences at Butler University.  His current research involves targeted delivery of siRNA and nanocomposites for the treatment of glioblastoma and triple negative breast cancers.  Dr. Das has over 150 research publications, review articles, patents, proceedings, conference presentations, and book chapters, is a recipient of multiple awards/honors, and has secured extramural research funding from NIH, PDA, and the pharmaceutical industry.

Since 2004, he has served on over 50 study sections for the NIH - Center for Scientific Review, and continues to serve on the editorial boards of Journal of Pharmaceutical Sciences (APhA and Elsevier), Therapeutic Delivery (Future Science Group, UK), Bioengineering (MDPI, Switzerland), Cancers (MDPI, Switzerland), and Pharmaceutics (MDPI, Switzerland)

Dr. Das has been an active member of AACP since 1994, where he became an AACP Leadership Fellow (2005), and served as the chair-elect, chair and immediate past chair of the Teachers of Pharmaceutics Section (2006-09).   From 2008-11, Dr. Das served as the founding chair and immediate past chair of the AACP Council of Sections, where he led the task of developing the mission and goals of the new council, and created various task forces supporting the missions of the AACP sections.  He has also served on the AACP Board of Directors (2008-11), AACP Research & Graduate Affairs and the Bylaws and Policy Development Committees, along with various AACP Task Forces.

Dr. Das is also an active member of AAPS (since 1991) and CRS (Controlled Release Society, since 1987).  He has served on many committees of the PDD/PPB and BIOTEC sections of AAPS

Research areas: Nanomedicine, non-viral gene therapy, translational research in glioblastoma and triple negative breast cancer, targeted delivery of anticancer drugs, ocular drug delivery, formulation development of poorly soluble drugs, pharmacokinetics and stability studies of pharmaceuticals.